Articles related to BREAST CANCER

Retrospective analyses presented at SABCS 2025 associated GLP-1 receptor agonist use with weight loss, mortality, and recurrence signals in breast cancer cohorts, with effects on endocrine therapy tolerability also observed.

The FDA approved vepdegestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy progression, marking the first regulatory approval of a PROTAC drug.

ACP updated guidance recommends shared decision-making rather than routine biennial mammography for average-risk women aged 40 to 49, diverging from the USPSTF recommendation.

Breast cancer screening remains a persistent area of variation in clinical practice. Updated guidance from the American College of Physicians aims to clarify when screening offers meaningful benefit for average‑risk patients — and when it may not.

Supplemental MRI for women with extremely dense breasts and higher-than-average risk “could be cost-effective if MRI costs and false-positive biopsy rates are reduced.” — Tosteson et al., Annals of Internal Medicine

“Basically women were told: ‘You’re lucky to be alive. Some pain is expected. Suck it up and deal with it.'” — Dr. Sean Mackey, Stanford University Pain Medicine